Collateral sensitivity is when cells’ vulnerability to a particular drug coincides with resistance to another. Hemann and Lauffenbuger Lab researchers conducted a comprehensive survey of collateral sensitivities associated with different combination chemotherapy regimens for cancer. Their findings, published in Scientific Reports, reveal that such responses are uncommon and heterogeneous, suggesting the existence of multiple different states of resistance.
This work was funded in part by the MIT Center for Precision Cancer Medicine and the Ludwig Center at MIT.